Your session is about to expire
← Back to Search
Emtricitabine for Alzheimer's Disease (LINE-AD Trial)
LINE-AD Trial Summary
This trial will study whether a daily oral dose of 200 mg emtricitabine can help improve memory in people with mild to moderate dementia due to Alzheimer's disease.
LINE-AD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLINE-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LINE-AD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your cerebrospinal fluid (CSF) test must show a pTau/Aβ42 ratio of more than 0.024.I do not have any conditions affecting my thinking or memory.I am between 50 and 85 years old.Your brain MRI shows something that could cause future memory problems, could be risky for you, or could make it hard to monitor your safety during the study.I have been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease.Your score on the Mini Mental State Exam (MMSE) is between 15 and 30.In the past six months, you have had thoughts of suicide or have engaged in suicidal behavior in the past two years.I have been on a stable dose of cholinesterase inhibitors and memantine for at least 60 days.You have mild to severe dementia, as measured by the Clinical Dementia Rating (CDR) scale.
- Group 1: Group 1
- Group 2: Group 2
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have enrolled in the experiment thus far?
"Affirmative, the information on clinicaltrials.gov affirms that this experiment is actively recruiting participants. Initially posted in December 2021 and most recently updated September 2022, the research seeks to enrol 35 individuals across a single medical centre."
Are there any criteria that would disqualify me from participating in this research?
"In order to qualify for participation in this clinical trial, candidates must have experienced cognitive decline and be aged between 50-85. The research is currently seeking 35 test subjects."
Does this research trial accept participants who are senior citizens?
"The requirements to partake in this medical trial are that the applicant is aged between 50 and 85. There are 979 trials for persons over 65 years old, while 55 clinical studies exist tailored specifically for individuals under 18 years of age."
Is there currently an opportunity for participants to join this research project?
"Evidenced by the clinicaltrials.gov data, this scientific exploration is open to volunteers. The trial was initially advertised on December 17th 2021 and has been modified most recently in September 14th 2022."
Has there been prior experimentation involving Group 1?
"Presently, 61 research initiatives concerning Group 1 are taking place. Of the active trials, 18 have progressed to Phase 3 of clinical testing. The majority of studies for Group 1 are located in Boylston, Massachusetts; however there is a total of 871 sites conducting these experiments all over the world."
What potential risks can individuals incur by being exposed to Group 1?
"Due to the scarcity of clinical evidence, Group 1 was assigned a score of 1 for safety. This is because this trial falls into Phase I, indicating minimal data on both efficacy and risk mitigation."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger